Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Going Global - Chime Biologics Embraces Innovation and Quality with Partners
Bing Chen, Vice President of International BD and Venture Fund at AstraZeneca mentioned that it was previously sufficient for innovative medicines to be a regional leader, but winning products now need to be best-in-class globally. By launching best-in-class products, Chinese pharmaceutical companies are more likely to attract additional global collaboration opportunities. Bing Chen, Vice President of International BD and Venture Fund at AstraZeneca mentioned that it was previously sufficient...
PR Newswire
05/07/2024
FDA approves Roche's Vabysmo prefilled syringe (PFS) for three leading causes of…
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindnessDesigned to simplify administration, Vabysmo PFS provides retina specialists a ready-to-use option Vabysmo PFS will be available for people living with nAMD, DME and RVO Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6...
Nasdaq GlobeNewswire
05/07/2024
Medsenic, subsidiary of BioSenic SA, extends key patent to the United States
PRESS RELEASE – PRIVILEGED INFORMATION The developed Medsenic's composition-of-matter patent family does cover the therapeutic use of arsenic salts and metal ions through various routes of administration.Medsenic's enriched IP portfolio is aimed at protecting medications involving the combination of arsenic trioxide (ATO) and copper ions, which have demonstrated increased therapeutic potential for indications ranging from immune to cancer and to infectious diseases. ...
Nasdaq GlobeNewswire
05/07/2024
BK Virus Infection Market to Witness Surge in Growth During the Study Period…
Key Takeaways from the BK Virus Infection Market Report Key Takeaways from the BK Virus Infection Market Report Discover which therapies are expected to grab the major BK virus infection market share @ BK Virus Infection Market Report BK Virus Infection Overview The BK virus (BKV) is a member of the polyomavirus family and is highly prevalent in the general population, often remaining latent in the kidneys. Infection typically occurs in childhood, but it remains asymptomatic in...
PR Newswire
04/07/2024
Major shareholder announcement – BlackRock, Inc.
4 July 2024 Major shareholder announcement – BlackRock, Inc. ANNOUNCEMENT NO. 271 Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 3 July 2024, increased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10...
Nasdaq GlobeNewswire
04/07/2024
KFSH&RC Achieves Remarkable 98% Survival Rate in 400 Robotic Cardiac Surgeries
RIYADH, Saudi Arabia, July04, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of today, 400 robotic cardiac surgeries have been performed with a remarkable 98% survival rate.KFSH&RC is leading a healthcare revolution by harnessing robotics to transform...
Nasdaq GlobeNewswire
04/07/2024
Declaration of shares and voting rights - Valneva SE - June 30, 2024
VALNEVADeclaration of shares and voting rightsJune 30, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: July 4, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the...
Nasdaq GlobeNewswire
04/07/2024
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on…
Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024.Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET,Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, informs its shareholders and the market that, at today's Extraordinary General Meeting, the attendance quorum required to deliberate and vote on the items on the agenda has not been reached, and that consequently, the...
Nasdaq GlobeNewswire
04/07/2024
Global Microscopy Market to Reach USD 10.6 Billion by 2029 driven by Healthcare…
Browse in-depth TOC on "Microscopy Market" Browse in-depth TOC on "Microscopy Market" 290 - Tables 62 - Figures 303 - Pages Key Players in the Microscopy Market: A Competitive Landscape The microscopy market features a competitive landscape dominated by major multinational corporations alongside significant contributions from SMEs and regional players. Key players includeCarl Zeiss AG( Germany ), Thermo Fisher Scientific (US), Danaher Corporation (US), EVIDENT ( Japan...
PR Newswire
04/07/2024
Digital Healthcare Market Size to reach $836.10 billion by 2031, growing at a…
Market Dynamics: Market Dynamics : The growth of digital healthcare market is driven by increasing adoption of telehealth and telemedicine. Telehealth allows remote consultation for the healthcare providers and patients which increases the convenience of treatment. During COVID-19 pandemic, telehealth witnessed exponential growth as it addressed the challenge of physical distancing. Moreover, growing usage of smartphones and tablets has fueled the demand for various healthcare apps for...
PR Newswire
04/07/2024
Sectra publishes Annual Report and Sustainability Report for 2023/2024
A summary of the financial year is also available on the website. The 2023/2024 financial year in brief summarizes the value we create for various stakeholders, highlights from our operations, and a selection of financial performance measures. A summary of the financial year is also available on the website.The 2023/2024 financial year in briefsummarizes the value we create for various stakeholders, highlights from our operations, and a selection of financial performance measures...
PR Newswire
04/07/2024
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim analysisThe combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy compared to the comparator armSafety was consistent with previous studies, however we intend to halt the trial due to reduced efficacy compared to the comparator armBasel, 04 July 2024 - Roche...
Nasdaq GlobeNewswire
04/07/2024
BCG Unresponsive NMIBC Market to Register Sustainable Growth During the Study…
Key Takeaways from the BCG Unresponsive NMIBC Market Report Key Takeaways from the BCG Unresponsive NMIBC Market Report Discover which therapies are expected to grab the major BCG unresponsive NMIBC market share @ BCG Unresponsive NMIBC Market Report BCG Unresponsive NMIBC Overview BCG unresponsive non-muscle invasive bladder cancer (NMIBC) is a condition where bladder cancer does not adequately respond to Bacillus Calmette-Guérin (BCG) therapy, a common intravesical treatment...
PR Newswire
03/07/2024
Aker ASA: Streamlining Aker BioMarine, crystallizing value and re-investing in…
Based on Aker BioMarine's estimated excess cash following closing, Aker BioMarine is planning to pay an extraordinary dividend of NOK 35 to NOK 45 per share. Accordingly, Aker expects to receive gross cash proceeds between NOK 2.4 and NOK 3.1 billion, subject to final purchase price adjustments and the contemplated refinancing of Aker BioMarine. After an equity investment in Aker BioMarine Antarctic Holding II AS in the area of NOK 1.4 billion and a shareholder loan in the area of NOK 200…
PR Newswire
03/07/2024
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews…
Annual Meeting Results Annual Meeting Results There was an exceptionally strong vote turnout at the 2023 Annual Meeting, with 961.7 million votes cast out of the total 1.2 billion shares outstanding as of the record date, comprising over 77% of all common and preferred shares outstanding. This vote turnout repeated the exceptional turnout at the 2022 Annual Meeting, where 841 million votes were cast comprising 78% of the total shares that were then outstanding. There were 5 Proposals...
PR Newswire
03/07/2024
Monthly information related to total number of voting rights and shares…
Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)voting rightsTotal of net(2)voting rights December 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 951...
Nasdaq GlobeNewswire
03/07/2024
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of…
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and Nantes, France, 3 July 2024– Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company (ISIN: FR0012127173; Mnemo: OSE), announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into the next phase in clinical development. As part of the program,...
Nasdaq GlobeNewswire
03/07/2024
IVI RMA Global and Lavima Fertility join forces in research in fertility…
Ovarian stimulation is the initial part of assisted reproduction treatments, and it is the phase of infertility treatments in which the least relevant advances have been achieved to date. It is one of the main psychological barriers for women when deciding to begin this path towards motherhood. Many of them are concerned about how this process may affect them physically and emotionally.With the aim of making progress in this field, IVI RMA GLOBAL has signed an exclusive agreement with...
Nasdaq GlobeNewswire
03/07/2024
Operating Room Management Market: Transforming Healthcare with USD 7.5 Billion…
Browse in-depth TOC on "Operating Room Management Market" Browse in-depth TOC on "Operating Room Management Market" 150 - Tables30 - Figures240 - Pages Competitive Landscape and Market Dynamics The operating room management market is highly competitive and trending towards consolidation. Key players include Oracle (Cerner Corporation), Epic Systems Corporation, GE Healthcare, and others. Oracle recently strengthened its position through the acquisition of Cerner,...
PR Newswire
03/07/2024
Exoskeleton Market to Surpass USD 23.6 Billion Valuation by 2031 On the Back of…
Download a detailed overview: Download a detailed overview: https://www.skyquestt.com/sample-request/exoskeleton-market Exoskeleton Market Overview: Segments covered in Exoskeleton Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/exoskeleton-market Powered Exoskeletons to Spearhead Revenue Generation Due to Their High Productivity Powered exoskeletons utilize motorized components and actuators to...
PR Newswire
03/07/2024
Medical Electronics Market worth $15.7 billion by 2029 - Exclusive Report by…
Browse in-depth TOC on "Medical Electronics Market" 120 – Tables70 – Figures260 – Pages Browse in-depth TOC on "Medical Electronics Market" 120 – Tables 70 – Figures 260 – Pages Medical Electronics Market Report Scope: Sensors segment based on components in the medical electronics market to grow with the highest growth rate. The highest surge of growth inmedical electronics is due to sensors, which play a crucial role in improving the functionality and accuracy of a wide...
PR Newswire
03/07/2024
Rosacea Therapeutics Market to Reach a Value of $8.41 Billion, Growing at a CAGR…
The growing adoption of telemedicine and digital healthcare solutions is transforming rosacea treatment, enabling remote consultations, follow-ups, and patient monitoring. These innovations enhance patient compliance and expand access to specialized treatments, particularly in underserved areas. Additionally, ongoing research and development efforts are poised to introduce cutting-edge treatments for rosacea, including novel oral medications, laser technologies, and topical formulations. The...
PR Newswire
03/07/2024
Avicenna.AI secures MDR certification for medical imaging AI portfolio
The MDR was introduced to update the EU's regulations for medical devices, addressing safety issues and the recent emergence of AI tools and software as a medical device (SaMD), which did not exist when the old regulations were created. Ensuring MDR compliance is a critical component of obtaining and maintaining CE-mark status, which allows a device to be freely traded in the EU. The MDR was introduced to update the EU's regulations for medical devices, addressing safety issues and the recent...
PR Newswire
03/07/2024
Invitation: Sobi's Q2 2024 report
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. To participate in the conference call, please use the following dial-in details:Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries, please...
PR Newswire
03/07/2024
Altri Comunicati
